Novo Nordisk gains following patent challenge win

  • Investing.com
  • Stock Market News
Novo Nordisk gains following patent challenge win
Credit: © Reuters.

Novo Nordisk (NYSE: NVO ) saw a nearly 1% rise in its stock price today after the U.S. Patent Office tribunal rejected challenges to two critical patents for its drugs Wegovy and Ozempic. These challenges were brought by Mylan Pharmaceuticals, a generic drugmaker aiming to produce generic versions of these medications.

Mylan, which is owned by Viatris Inc (NASDAQ: VTRS ), had argued that the patents should be invalidated because they were based on the anti-diabetes medication liraglutide. The tribunal denied Mylan's requests to review the Wegovy and Ozempic patents.

Mylan has additionally challenged a third patent connected to a treatment method involving these medications. The board is set to announce its decision on whether to review this patent by Friday. Novo Nordisk said it plans to vigorously defend its intellectual property.

Wegovy, a groundbreaking weight-loss drug, has enjoyed significant sales, leading to predictions by some analysts that the obesity market could surpass $100 billion by the decade's end. Novo's profits from Wegovy and Ozempic have contributed to its status as Europe's most valuable company as of September.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100
  • Peter Simons @Peter Simons
    While spending a successful man will always have thought of the future, that's why most rich men keep getting rich, they indulge in one form of investment in order to stay ahead of the countries economy, my advice for you today, is that you message a financial expert trader MR eric at +1 2 702 433 37 1 on WAATSAP and start a tangible profitable investment..
    Like 2

Related Articles